Search
Austin, TX Paid Clinical Trials
A listing of 625 clinical trials in Austin, TX actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
469 - 480 of 625
There are currently 625 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Childrens Medical Center of Central Texas, Pfizer Investigational Site and University of Texas at Austin. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
Recruiting
POWER PAD 2 is a prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular Systems (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™) System for treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Ascension Seton, Austin, Texas
Conditions: Peripheral Arterial Disease (PAD)
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Austin, Texas
Conditions: HER2 Positive Metastatic Breast Cancer
Sensor-controlled Digital Game for Heart Failure Self-management: A Clinical Trial
Recruiting
This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of weight monitoring and physical activity in adults with heart failure (HF). Half of the participants will receive the SCDG app and weight monitoring and physical activity sensors and the other half will receive only the weight monitoring and physical activity sensors.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
01/16/2025
Locations: The University of Texas Austin, Austin, Texas
Conditions: Heart Failure
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.
Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Texas Oncology- Austin Midtown, Austin, Texas
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
A Study of STAR-0310 in Healthy Adult Participants
Recruiting
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/15/2025
Locations: Austin Clinical Research Unit - Early Clinical Development, Austin, Texas
Conditions: Healthy Participants
Effect of Acute Nitrate Supplementation on Vascular Function in Hispanic, Black and White Population
Recruiting
The purpose of the study is to assess vascular function in African Americans, Hispanic and Caucasian Americans to better understand racial differences in cardiovascular health. The investigators will further investigate the affect of Beetroot juice on the vascular function of all participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/13/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Healthy Adults
Spine Procedures Assisted with RoboTics and Navigation
Recruiting
Creation of a pediatric robotic spine surgery registry will allow for data collection and analysis on the coupled use of robotics and navigation, as well as patient-specific rods in pediatric spine deformity surgery across participating study institutions. Eventually, an educational and informative framework for this technology will be established.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
01/13/2025
Locations: Dell Children's Medical Center, Austin, Texas
Conditions: Spine Deformity, Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis, Spondylolisthesis, Congenital Scoliosis, Neuromuscular Scoliosis
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Recruiting
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/10/2025
Locations: Sarah Cannon - St. David South Austin Medical Center, Austin, Texas
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
Acute Alcohol Response in Bipolar Disorder: a Longitudinal Alcohol Administration/fMRI Study
Recruiting
Alcohol use disorders (AUDs) affect up to 60% of individuals with bipolar disorder during their lifetime and is associated with worse illness outcomes, yet few studies have been performed to clarify the causes of this comorbidity. Understanding biological risk factors that associate with and predict the development of AUDs in bipolar disorder could inform interventions and prevention efforts to reduce the rate of this comorbidity and improve outcomes of both disorders. Identifying predictors of... Read More
Gender:
ALL
Ages:
Between 21 years and 26 years
Trial Updated:
01/08/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Bipolar Disorder, Alcohol Drinking, Alcohol Use Disorder
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Recruiting
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline tr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/07/2025
Locations: Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas
Conditions: Major Depressive Disorder, Chronic Major Depression, Recurrent
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: NEXT Austin, Austin, Texas
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care in Texas
Recruiting
The overall aim of this study is to reduce suicide among sexual and gender diverse youth ages 18-24 years old. This study will compare the effectiveness of two brief suicide prevention interventions that have been adapted for use with this population to use in primary care via telehealth and will recruit youth from primary care clinics in Texas metropolitan areas. The primary study outcome is suicidal ideation. Each clinic will be randomly assigned to deliver one of the two study interventions.
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
01/02/2025
Locations: Steve Hicks School of Social Work at the University of Texas at Austin, Austin, Texas
Conditions: Suicide, Suicidal Ideation
469 - 480 of 625